Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
NCT ID: NCT03806049
Last Updated: 2021-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2019-12-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
NCT05009082
Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer
NCT02354131
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
NCT05126342
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
NCT05751629
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A: triplet
chemotherapy-free combination of niraprib + bevacizumab + Dostarlimab
Niraparib
given orally once daily
Bevacizumab
given as iv infusion every three weeks
TSR042
Given as IV infusion every three weeks
B: Doublet
chemotherapy-free combination of niraparib + bevacizumab
Niraparib
given orally once daily
Bevacizumab
given as iv infusion every three weeks
C: standard of care
Standard of care chemotherapy: Carboplatin + paclitaxel
Carboplatin
given as iv infusion every three weeks
Paclitaxel
given as iv infusion every three weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Niraparib
given orally once daily
Bevacizumab
given as iv infusion every three weeks
TSR042
Given as IV infusion every three weeks
Carboplatin
given as iv infusion every three weeks
Paclitaxel
given as iv infusion every three weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. High-grade serious or high-grade endometrioid histology or any histology with known BRCA mutation.
3. Patient consents to perform BRCA test, and PD-L1 expression.
4. Prior line of therapy: Patients must have received platinum-containing therapy for primary disease.
5. No limits on number of platinum-based therapies.
6. Up to one non-platinum-based line of therapy in recurrent setting is allowed.
7. Patients may have received bevacizumab (or other anti-VEGF therapy) prior to entering in the trial.
8. Patients may have participated in a PARP inhibitor maintenance trial or have received maintenance PARP inhibitor therapy are allowed, though it is necessary to unblind patient in order to correctly stratify. Patients who received a PARP inhibitor as definitive are not eligible. Patients may have participated in a trial containing immune-checkpoint inhibitor.
9. Target group: Age 18+
10. Histological confirmed ovarian, fallopian tube or peritoneal cancers
11. Patients must give informed consent
12. Patients may have undergone primary or interval debulking surgery
13. Patients may have received bevacizumab or other anti-angiogenic therapy
14. Patients may have received a PARP inhibitor as first-line maintenance therapy.
15. Patients must have disease that is measurable according to RECIST or assessable according to the GCIG criteria
16. The patient agrees to complete PROs (QoL questionnaire) during study treatment AND at one additional time point 8 weeks following progression of disease
17. ECOG performance status 0-2
18. Adequate organ function
1. Absolute neutrophil count (ANC) ≥1,5 x 109/L
2. Platelets \>100 x 109/L
3. Hemoglobin ≥ 9g/dl
4. Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥50mL/min using Cockcroft-Gault formula
5. Total bilirubin ≤1.5x ULN
6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN unless liver metastases are present, in which case they must be ≤5x ULN.
19. Able to take oral medications
20. Life expectancy of at least 12 weeks
21. Patients must fulfill all inclusions criteria and according to investigator fit to receive niraparib, bevacizumab and TSR042.
22. Women of childbearing potential must use adequate birth control for the duration of study participation -
* Uncontrolled pulmonary embolism (PE)
* Deep venous thrombosis (DVT)
* Other related conditions, though patients with stable therapeutic anticoagulation for more than three months prior randomization are eligible for this study. This also apply to PE \& DVT.
12\. History of a cerebral vascular accident, transient ischemic attack or subarachnoid hemorrhage within the past 3 months 13. History of clinically significant hemorrhage in the past 3 months 14. Uncontrolled and/or symptomatic CNS metastasis or leptomeningeal carcinomatosis (Dexamethasone/prednisone therapy will be allowed if administered as stable dose for at least one month prior randomization) 15. Significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months prior to randomization, congestive heart failure \> NYHA III, severe peripheral vascular disease, QT prolongation \>470 msec ,clinically significant pericardial effusion 16. Pregnancy or breastfeeding. Patients with preserved reproductive capacity, unwilling to use a medically acceptable method of contraception for the duration of the trial and for 3 months afterwards.
17\. Radiographic evidence of cavitation or necrotic tumors with invasion of adjacent major blood vessels 18. Active or chronic hepatitis C and/or B infection 19. Persistence of clinically relevant therapy related toxicity from previous chemotherapy 20. Proteinuria as demonstrated by: (a) urine protein: creatinine (UPC) ratio \>/= 1.0 at screening OR (b) urine dipstick for proteinuria \>/=2+ (patients discovered to have \>/=2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hr urine collection and must demonstrate \</=1g of protein in24 hours to be eligible 21. Patients must not have any known history of MDS 22. Patients must not have known persistent (\> 4 weeks) ≥ Grade 2 hematological toxicity from prior cancer therapy 23. Patients must not have known ≥ Grade 3 thrombocytopenia or anemia with the last chemotherapy regimen.
18 Years
100 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MANSOOR RAZA R MIRZA
Role: STUDY_CHAIR
NSGO
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NSGO
Copenhagen, Region Sjælland, Denmark
Rigshospitalet
Copenhagen, Region Sjælland, Denmark
Rigshospitalet
København Ø, Region Sjælland, Denmark
Aalborg University Hospital
Aalborg, , Denmark
Tampere University Hospital
Tampere, , Finland
Haukeland University Hospital
Bergen, Haukeland, Norway
Norwegian Radium Hospital
Oslo, , Norway
The Norwegian Radium Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENGOT-OV42 / NSGO-AVATAR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.